kanamütsiin

Kanamütsiin is an aminoglycoside antibiotic used to treat serious bacterial infections. It is effective against a wide range of Gram-negative bacteria, including many strains that are resistant to other antibiotics. Kanamütsiin is typically administered intravenously or intramuscularly. It works by inhibiting bacterial protein synthesis, which is essential for bacterial growth and survival. Due to its potential for nephrotoxicity (kidney damage) and ototoxicity (hearing damage), its use is generally reserved for situations where other, safer antibiotics are not effective or appropriate. Monitoring of kidney function and hearing may be necessary during treatment. Kanamütsiin is not absorbed well from the gastrointestinal tract, so oral administration is not effective for systemic infections. It has been used in the treatment of tuberculosis, particularly in cases of multidrug-resistant strains. However, its role in current tuberculosis treatment regimens has diminished with the availability of newer and safer drugs. Kanamütsiin's mechanism of action involves binding to the 30S ribosomal subunit of bacteria, interfering with the correct reading of mRNA and leading to the production of faulty proteins.